Literature DB >> 4352365

Vincristine treatment of advanced cancer: a cooperative study of 392 cases.

J F Holland, C Scharlau, S Gailani, M J Krant, K B Olson, J Horton, B I Shnider, J J Lynch, A Owens, P P Carbone, J Colsky, D Grob, S P Miller, T C Hall.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4352365

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  37 in total

1.  Partially reversible nerve deafness due to vincristine.

Authors:  H Yousif; S G Richardson; W A Saunders
Journal:  Postgrad Med J       Date:  1990-08       Impact factor: 2.401

Review 2.  Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications.

Authors:  Julienne E Bower; Donald M Lamkin
Journal:  Brain Behav Immun       Date:  2012-07-06       Impact factor: 7.217

Review 3.  Intrathecal vincristine: a fatal chemotherapeutic error with devastating central nervous system effects.

Authors:  P G Bain; P L Lantos; V Djurovic; I West
Journal:  J Neurol       Date:  1991-07       Impact factor: 4.849

4.  Recurrent laryngeal nerve paralysis in patients receiving vincristine and vinblastine.

Authors:  J A Whittaker; I P Griffith
Journal:  Br Med J       Date:  1977-05-14

5.  Vincristine-induced neuropathy in rat: electrophysiological and histological study.

Authors:  Feras M H Ja'afer; Farqad B Hamdan; Faiq H Mohammed
Journal:  Exp Brain Res       Date:  2006-05-31       Impact factor: 1.972

Review 6.  [Chemotherapy-induced neuropathy].

Authors:  W Boehmerle; P Huehnchen; M Endres
Journal:  Nervenarzt       Date:  2015-02       Impact factor: 1.214

7.  Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia.

Authors:  Sindhu Ramchandren; Marcia Leonard; Rajen J Mody; Janet E Donohue; Judith Moyer; Raymond Hutchinson; James G Gurney
Journal:  J Peripher Nerv Syst       Date:  2009-09       Impact factor: 3.494

8.  Acute encephalopathy associated with continuous vincristine sulfate combination therapy: case report.

Authors:  W Scheithauer; H Ludwig; E Maida
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

9.  Clinical trial of pyridoxine to reduce vincristine neurotoxicity.

Authors:  D V Jackson; E K Pope; R A McMahan; M R Cooper; J N Atkins; R D Callahan; E H Paschold; R A Grimm; J O Hopkins; H B Muss
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

10.  Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma.

Authors:  S Koeppen; C C P Verstappen; R Körte; M E Scheulen; D Strumberg; T J Postma; J J Heimans; P C Huijgens; B Kiburg; K Renzing-Köhler; H C Diener
Journal:  J Cancer Res Clin Oncol       Date:  2004-01-16       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.